Advances in Immunology, a long established and highly respected serial, presents current developments as well as comprehensive reviews in immunology. Articles address the wide range of topics that comprise immunology, including molecular and cellular activation mechanisms, phylogeny and molecular evolution, and clinical modalities. Edited and authored by the foremost scientists in the field, each volume provides up-to-date information and directions for future research.
Inhaltsverzeichnis
1;Cover;2 2;Copyright Page;4 3;Contents;6 4;Contributors;10 5;Chapter 1: Class Switch Recombination: A Comparison Between Mouse and Human;12 5.1;1. Introduction;12 5.2;2. Mechanism of CSR;13 5.2.1;2.1. Class Switch Recombination "ABC";13 5.2.2;2.2. V(D)J Recombination and CSR;14 5.2.3;2.3. CSR and Somatic Hypermutation;14 5.2.4;2.4. Function of AID;15 5.2.5;2.5. dU:dG Mismatches Processing and DNA DSB Resolution in CSR;16 5.2.6;2.6. Regulation of CSR;22 5.3;3. Comparison Between Human and Mouse;26 5.3.1;3.1. The Constant Region Gene Locus in Human and Mouse;26 5.3.2;3.2. Switch Regions in Human and Mouse;27 5.3.3;3.3. 3' Enhancers in Human and Mouse;33 5.3.4;3.4. AID in Human and Mouse;36 5.3.5;3.5. Regulation of CSR to IgA in Human and Mouse;37 5.3.6;3.6. Regulation of CSR to IgG Subclasses in Human and Mouse;38 5.3.7;3.7. CD40-CD40L Pathway in Human and Mouse;42 5.3.8;3.8. BAFF-APRIL-TACI Pathway in Human and Mouse;43 5.3.9;3.9. Toll and Toll-Like Receptor in Human and Mouse;44 5.3.10;3.10. DNA Repair Factors and CSR;45 5.4;4. Concluding Remarks;53 5.5;Notes added in proof;53 5.6;Acknowledgments;54 5.7;References;54 6;Chapter 2: Anti-IgE Antibodies for the Treatment of IgE-Mediated Allergic Diseases;74 6.1;1. Introduction;75 6.1.1;1.1. The Current Status of the Anti-IgE Development;75 6.1.2;1.2. The Main Chemical Features of the Anti-IgE Therapeutic;76 6.1.3;1.3. IgE-Mediated Allergy Is a Vast Medical Field;77 6.2;2. Rationale Leading to the Invention of the Anti-IgE Concept;78 6.2.1;2.1. IgE Isotype-Specific Control and IgE Targeting;78 6.2.2;2.2. The Unique Set of Anti-IgE-Binding Specificities;79 6.2.3;2.3. Structural Basis of the Unique Binding Specificities;80 6.2.4;2.4. Prevailing Concepts at the Time of the Invention;82 6.3;3. Anti-IgE Is Approved for Treating Moderate-to-Severe Asthma;84 6.3.1;3.1. "Allergic Asthma" Has Been Adopted as a New Clinical Indication;85 6.3.2;3.2. Clinical Parameters Determined in the Clinical Studies;86 6.3.3;3.3. The Clinical
Studies Confirm the Roles of IgE in the Pathogenesis of Asthma;88 6.3.4;3.4. Analyses of Good Responders Among Asthma Patients;89 6.4;4. Studies on Other Allergic Diseases;89 6.4.1;4.1. Clinical Applications in Treating Allergic Rhinitis;90 6.4.2;4.2. Anti-IgE Studies on Treating Peanut Sensitivity;91 6.4.3;4.3. Clinical Application in Latex Sensitivity;92 6.4.4;4.4. Allergic Diseases or Conditions for Which Anti-IgE Has Been Tested in Case Studies;92 6.5;5. The Potential of Using Anti-IgE to Assist Allergen-Based Immunotherapy;94 6.5.1;5.1. The Combination of Anti-IgE and SIT;95 6.5.2;5.2. Priming Patients with Anti-IgE for Rush Immunotherapy;95 6.6;6. Pivotal Roles of IgE and FcepsivRI in Type I Hypersensitivity;96 6.6.1;6.1. Stages Along IgE-Mediated Allergic Pathway;96 6.6.2;6.2. Direct Pharmacological Effects of Anti-IgE;98 6.7;7. Neutralization of Free IgE;99 6.7.1;7.1. Total IgE and the Proportion of Allergen-Specific IgE;99 6.7.2;7.2. IgE Concentration versus IgE Occupancy of FcepsivRI;100 6.8;8. Downregulation of FcepsivRI;101 6.8.1;8.1. The Dynamical Relationship Between Free IgE and FcepsivRI;101 6.8.2;8.2. Anti-IgE as a Mast "Cell-Stabilizing" Agent;102 6.8.3;8.3. How Low Should FcepsivRI-IgE Fall for a Mast Cell to Become Insensitive?;103 6.9;9. Potential Beneficial Effects of IgE:Anti-IgE Immune Complexes;104 6.9.1;9.1. How Soon Can Clinical Improvement Be Observed?;104 6.9.2;9.2. The Rapidly Accumulated Immune Complexes May Serve as Antigen Trappers;106 6.10;10. Can Anti-IgE Modulate IgE-Committed B Lymphoblasts and Memory B Cell?;107 6.11;11. Other Immunoregulatory Effects of Anti-IgE;109 6.11.1;11.1. Anti-IgE Should Neutralize the Cytokinergic Properties of IgE;109 6.11.2;11.2. The Overall Attenuation of Immune Reactivity;110 6.11.3;11.3. Local Environment in Disease-Affected Tissues is of Utmost Interest;110 6.12;12. Can Anti-IgE Attain a Long-Term Remission State?;111 6.13;13. Are There Adverse Effects Associated with Anti-IgE Therapy?;112 6.13.1;
13.1. Is Immune Defense Function Compromised?;112 6.13.2;13.2. Observed Adverse Reactions;114 6.14;14. Other Approaches for Targeting IgE or IgE-Expressing B Cells;114 6.14.1;14.1. Approaches for Attenuating IgE-Mediated Allergic Pathway;114 6.14.2;14.2. An Approach to Target a Unique Epitope on mIgE;115 6.15;15. Concluding Remarks;117 6.16;Acknowledgments;118 6.17;References;118 7;Chapter 3: Immune Semaphorins: Increasing Members and Their Diverse Roles;132 7.1;1. Introduction;132 7.2;2. Sema4D;133 7.2.1;2.1. Sema4D-CD72 Interactions in B Cell Signaling;134 7.2.2;2.2. Sema4D-CD72 Interactions in Maintaining B Cell Homeostasis;135 7.2.3;2.3. Sema4D in T Cell-Mediated Immunity;137 7.3;3. Sema4A;138 7.3.1;3.1. Distinct Roles of DC-Derived and T Cell-Derived Sema4A in Immune Responses;138 7.3.2;3.2. Receptors for Sema4A in the Immune System;141 7.4;4. Sema6D and Its Receptor Plexin-A1;141 7.4.1;4.1. Sema6DPlexin-A1 Interactions in Cardiac Development;142 7.4.2;4.2. Sema6D-Plexin-A1 Interactions in DC Function;142 7.4.3;4.3. Sema6DPlexin-A1 Interactions in Osteoclastogenesis;143 7.4.4;4.4. Plexin-A1 Forms a Receptor Complex with TREM-2 and DAP12 in DCs and Osteoclasts;143 7.5;5. Sema7A;146 7.5.1;5.1. Sema7A as a Monocyte Stimulator;146 7.5.2;5.2. Sema7A as a Negative Regulator for T Cells;147 7.6;6. Other Semaphorins;148 7.6.1;6.1. Viral Semaphorins;148 7.6.2;6.2. Class III Semaphorins;148 7.7;7. Summary and Perspectives;149 7.8;Acknowledgments;150 7.9;References;150 8;Chapter 4: Tec Kinases in T Cell and Mast Cell Signaling;156 8.1;1. Introduction;156 8.1.1;1.1. Overview of Tec Kinases;156 8.1.2;1.2. Regulation of Tec Kinase Expression Levels;157 8.2;2. Subcellular Localization of Tec Kinases;158 8.2.1;2.1. Regulation of Membrane Recruitment;158 8.2.2;2.2. Nuclear Localization and Functions of Tec Kinases;161 8.3;3. Tec Kinases in Signaling Pathways;162 8.3.1;3.1. Antigen Receptor Signaling Pathways;162 8.3.2;3.2. Interactions with Negative Regulators of Signaling;165
8.3.3;3.3. Interactions with the Cytoskeletal Components;167 8.3.4;3.5. Associations with Additional Signaling Proteins;168 8.4;4. Regulation of Tec Kinase Activation;171 8.4.1;4.1. Regulation by Tyrosine Phosphorylation;171 8.4.2;4.2. Inter- and Intramolecular Domain Interactions;172 8.5;5. Distinct Versus Redundant Functions of Tec Kinases;174 8.5.1;5.1. Tec Kinases in T Cell Development;174 8.5.2;5.2. Tec Kinases in Other Cell Types;175 8.5.3;5.3. Redundancy Among Tec Kinase Family Members;175 8.6;6. Tec Kinases in Mast Cell Signaling;177 8.6.1;6.1. Overview of Mast Cells;177 8.6.2;6.2. FcepsilonR1 Signaling;178 8.6.3;6.3. Btk in Mast Cell Function and Signaling;180 8.6.4;6.4. Possible Role of Ikt in Mast Cells;181 8.6.5;6.5. Potential Positive Roles of Multiple Tec Kinases in Mast Cells;181 8.6.6;6.6. Potential Negative Roles for Tec Kinases in Mast Cell Signaling;182 8.7;7. Conclusions;183 8.8;Acknowledgments;183 8.9;References;183 9;Chapter 5: Integrin Regulation of Lymphocyte Trafficking: Lessons from Structural and Signaling Studies;196 9.1;1. Introduction;196 9.2;2. Leukocyte Integrins;197 9.3;3. Affinity and Valency Regulation;200 9.4;4. Integrin Conformational Changes;200 9.4.1;4.1. Global Changes of Extracellular Domains in Integrins That Lack the alphal Domains;200 9.4.2;4.2. Extensions of Extracellular Domains of beta2 Integrins;201 9.4.3;4.3. Multiple Affinity States of the alphal Domain;203 9.4.4;4.4. Regulation of the alphaI Domain Conformations by the betaI Domain;203 9.4.5;4.5. Regulation of the betaI Domain by Extensions and Divalent Metals;203 9.4.6;4.6. Cytoplasmic Domain;204 9.5;5. Integrin-Mediated Adhesion Steps in Lymphocyte Trafficking;206 9.5.1;5.1. Conversion of Rolling to Firm Adhesion by Chemokines;206 9.5.2;5.2. Transmigration;210 9.5.3;5.3. Interstitial Migration in Lymphoid Tissues;210 9.5.4;5.4. Interactions with APC;211 9.6;6. Talin as Intracellular Regulator for Lymphocyte Adhesion and Migration;212 9.7;7. Intracellular Signals i
n Chemokine-Induced Adhesion and Migration;214 9.7.1;7.1. PI3K Pathways;214 9.7.2;7.2. Rho Pathways;215 9.7.3;7.3. Rap1 Pathways;216 9.7.4;7.4. Rac Pathways;219 9.7.5;7.5. RhoH;221 9.8;8. Inside-Out Signaling Events in TCR-Stimulated Lymphocytes;222 9.8.1;8.1. Tec Family Kinases;223 9.8.2;8.2. Rac Signaling Pathways;223 9.8.3;8.3. Rap1 Signaling Pathways;224 9.8.4;8.4. PKD 1;225 9.8.5;8.5. Adhesion and Degranulation Adaptor Protein;225 9.9;9. Concluding Remarks;226 9.10;Acknowledgments;226 9.11;References;227 10;Chapter 6: Regulation of Immune Responses and Hematopoiesis by the Rap1 Signal;240 10.1;1. Introduction;240 10.2;2. General Biology of the Rap1 Signal;241 10.2.1;2.1. Regulation of Rap1 Activation;241 10.2.2;2.2. Biological Function of Rap1;244 10.3;3. Rap1 Signal in Lymphocyte Development and Immune Responses;248 10.3.1;3.1. Thymic T Cell Development: Distinct Roles of Rap1 and Ras;248 10.3.2;3.2. Immunological Synapse and T Cell Activation;251 10.3.3;3.3. T Cell Nonresponsiveness and Anergy;252 10.3.4;3.4. B Cell Development and Self-Tolerance;255 10.3.5;3.5. Lymphocyte Migration and Homing;258 10.4;4. Rap1 Signal in Hematopoiesis and Leukemia;259 10.4.1;4.1. Hematopoietic Stem Cells and the Niche;259 10.4.2;4.2. Dysregulated Rap1 Signal and Myeloproliferative Disorders;260 10.4.3;4.3. Role of Rap1 in Generation and Function of Platelets;264 10.5;5. Rap1 Signal in Malignancy: New Aspects in Cancer;264 10.6;6. Conclusions and Perspectives;266 10.7;Acknowledgments;266 10.8;References;267 11;Chapter 7: Lung Dendritic Cell Migration;276 11.1;1. Introduction;276 11.2;2. Airway DC Subsets: Localization and Phenotype;277 11.3;3. Recruitment of DCs to the Lung;278 11.4;4. Migration of Airway DCs to the LNs;280 11.4.1;4.1. Migration of DCs Under Steady-State Conditions;280 11.4.2;4.2. Migration of DCs Under Inflammatory Conditions;281 11.5;5. Recruitment of pDCs to the Sites of Inflammation;283 11.6;6. Conclusions;283 11.7;References;284 12;Index;290 13;Contents of
Recent Volumes;302